Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Meiji Seika Aims at \10 Bil. Sales with Generics
January 21, 2008
- NEW PRODUCTS／Dinagest Tablet for Endometriosis: Mochida
January 21, 2008
- Taisho Licenses TS-032 to Pfizer
January 21, 2008
- Tacere to Codevelop RNAi Hepatitis C Drug with Pfizer
January 21, 2008
- Mochida Licenses Analgesic to Wyeth
January 21, 2008
- Toyama Starts PII Study for T-705
January 21, 2008
- Novartis to Close Its Tsukuba Research Institute
January 21, 2008
- R&D NEWS IN BRIEF
January 21, 2008
- How Can I Grow My Brand without Growing My Budget?
January 21, 2008
- SURVEY／Patients with Serious Diseases More Likely to Quit Smoking
January 21, 2008
- Excessive Rebates May Violate Antimonopoly Law: Ihoken
January 21, 2008
- Teijin Pharma Enters US Market for Home Healthcare Equipment
January 21, 2008
- All Concerned Parties Should Cooperate to Improve Business Practices: Mr Matsutani
January 21, 2008
- Health Net and Med-Solution to Form Alliance for Clinical Imaging Studies
January 21, 2008
- PMDA to Expand Review System for Generics, OTC Drugs: Chief Executive Miyajima
January 21, 2008
- MEDICAL DEVICE NEWS IN BRIEF
January 21, 2008
- Korosho to Expand System to Determine Market Trend for Generics
January 21, 2008
- Reimbursement Prices for 5 Chemotherapy Regimens under DPC System to Be Reconsidered
January 21, 2008
- Nichi-Iko Improves Distribution, Production Systems to Ensure Overnight Deliveries
January 21, 2008
- Int'l Cooperation Needed to Eliminate Counterfeit Drugs: Prof. Kimura
January 21, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…